ICM; Medecine B3
Montpellier Cedex 5, France
Cancer treatment center in Montpellier
🇪🇺 Euromedicine Park, 208 Av. des Apothicaires, 34090 Montpellier
About ICM; Medecine B3
"L’Institut du Cancer de Montpellier (ICM) est le centre de référence en Occitanie-Est, reconnu au niveau national pour son expertise et son innovation dans la prise en charge et le traitement des patients atteints de cancers : cancer du sein, cancers digestifs (colon, rectum, pancréas…), cancers gynécologiques (col de l’utérus, ovaires…), cancer de la prostate, cancer du poumon, sarcomes, cancer ORL... La prise en charge et l’accompagnement des patients atteints de cancer à Montpellier et dans toute la région est assurée par des équipes médicales pluridisciplinaires spécialisées. Il regroupe des unités de soins, de prévention, de recherche clinique, translationnelle et fondamentale en cancérologie. L’ICM fait partie du réseau UNICANCER."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at ICM; Medecine B3
During the past decade, ICM; Medecine B3 conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on
average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
2004-09-01
2005-10-01
Completed
947
IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting
2005-05-01
2009-08-01
Completed
34,810
Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial
2004-04-01
2005-10-01
Completed
419
Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure
2010-01-01
Completed
170
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
2012-11-13
2019-02-28
Terminated
156
Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
2012-10-23
2020-10-26
Completed
68
Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries
2013-06-03
2021-06-22
Completed
442
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at ICM; Medecine B3
According to Clinical.Site data, the most researched conditions in "ICM; Medecine B3" are
"Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "ICM; Medecine B3" in a lesser frequency.
Clinical Trials Intervention Types at ICM; Medecine B3
Most popular intervention types in "ICM; Medecine B3" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody" (1 trials), "Gemcitabine" (1 trials), "Ipatasertib" (1 trials), "Paclitaxel" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.
Clinical Trials Genders at ICM; Medecine B3
The vast majority of trials in "ICM; Medecine B3" are
2 trials for "All" genders.
Clinical Trials Status at ICM; Medecine B3
Currently, there are NaN active trials in "ICM; Medecine B3".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in ICM; Medecine B3,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in ICM; Medecine B3, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 1 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".